Page last updated: 2024-08-24

topotecan and imatinib mesylate

topotecan has been researched along with imatinib mesylate in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P1
Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L1
Hayakawa, Y1
de Cremoux, P; Decaudin, D; Fréneaux, P; Judde, JG; Livartowski, A; Nemati, F; Pouillart, P; Poupon, MF; Sastre, X; Tran-Perennou, C1
Berardi, AC; Dominici, C; McDowell, HP; Meco, D; RaschellĂ , G; Riccardi, A; Riccardi, R; Tanno, B1

Reviews

1 review(s) available for topotecan and imatinib mesylate

ArticleYear
In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    International journal of cancer, 2005, Feb-20, Volume: 113, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Small Cell; Cell Proliferation; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Topotecan; Transplantation, Heterologous

2005

Other Studies

4 other study(ies) available for topotecan and imatinib mesylate

ArticleYear
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
    Cancer research, 2004, Apr-01, Volume: 64, Issue:7

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan

2004
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
    Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:8

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan

2002
[Structure-activity relationship analysis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine

2004
Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.
    International journal of cancer, 2007, Mar-01, Volume: 120, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Rhabdomyosarcoma; RNA, Messenger; Topotecan; Xenograft Model Antitumor Assays

2007